Novel blood-based proteomic signatures across multiple neurodegenerative diseases
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
INTRODUCTION
Blood-based biomarkers have the potential to support early and accurate diagnosis of neurodegenerative diseases, which is sensitive to molecular pathology and predictive of outcome. We evaluated a novel multiplex proteomic method in people with diverse neurodegenerative diseases.
METHODS
Serum from people with Alzheimer’s disease (N=36), Lewy body dementia (N=34), frontotemporal dementia (N=36) and progressive supranuclear palsy (N=36) and age-matched controls (N=30) was analysed with the NUcleic acid Linked Immuno-Sandwich Assay (NULISA) central nervous system panel (∼120 analytes) and inflammation panel (250 analytes). Biomarkers were compared across groups and included as predictors of survival.
RESULTS
The NULISA panels demonstrated high sensitivity and reliability for detecting multiple biomarkers across neurodegenerative disorders. There were condition-specific proteomic biomarkers, while NfL, CRH, CD276 and S100A12 were significant transdiagnostic outcome predictors.
DISCUSSION
The sensitive NULISA multiplex approach supports differential diagnosis and target identification, with prognostically informative dementia-related biomarkers.
